Latest Views & News

Accrol – hopefully prior warnings here were heeded as now a further profit warning and a “strategic review”

By Steve Moore | Wednesday 12 January 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Previously writing on “the UK’s leading independent tissue converter” Accrol (ACRL) in October with the shares falling below 40p, I concluded that the group argues the latest are “short-term external challenges”, but also raw material supply chains “further tightening in recent weeks”. As such, hopefully the prior warning was heeded and the stance remains avoid. Today a further trading update and the shares… further down to 25p. So what’s the latest?…

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

|